STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro
A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
STAR PH 2 ASG-22CE Urothelial Cancer
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More
Phase: I/II
FLEX Registry: Evaluate New Gene Express
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More
Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial
Phase: III
STAR Ph 3 Tuca/Placbo + T-DM1 HER2+
STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016) Read More
Phase: III
PH3 Plac Carbo Pacil Dura +/- Olap DUO-E
D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) Read More
Phase: III
STAR Ph3 Sinti vs Placebo ESCC
A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301 Read More
Phase: III
STAR PH3 Pacritinib vs MD choice in MF
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More
Phase: III
STAR PH3 Pacritinib vs MD choice in MF
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More
Phase: III
STAR Infigratinib vs Gem/Cis Cholangio
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More
Phase: III
STAR Infigratinib vs Gem/Cis Cholangio
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More
Phase: III
STAR Ublituximab+TGR-1202 Cross-over
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More
Phase: II
STAR Ublituximab+TGR-1202 Cross-over
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More
Phase: II
PH3 AMG 510 vs Doce a/mNSCLC
20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C Read More
Phase: III
PH3 AMG 510 vs Doce a/mNSCLC
20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C Read More
Phase: III
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More
Phase: I/II
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More
Phase: I/II
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) Read More
Phase: III
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) Read More
Phase: III
STAR KEAP1/NRF2 NSCLC
CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) Read More
Phase: II
STAR KEAP1/NRF2 NSCLC
CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) Read More
Phase: II
STAR BV in older pts w/1L cHL or PTCL
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read More
Phase: II
STAR BV in older pts w/1L cHL or PTCL
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read More
Phase: II
EAP BGB-3111 B-Cell Malig
A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216) Read More
EAP BGB-3111 B-Cell Malig
A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216) Read More
STAR PH3 Pacritinib vs MD choice in MF
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More
Phase: III
STAR PH3 Pacritinib vs MD choice in MF
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More
Phase: III
Ph 3 Chemo +/- Pembro/Olap EOC
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK7339-001/ENGOT-ov43/GOG-3036) Read More
Phase: III
Ph 3 Chemo +/- Pembro/Olap EOC
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK7339-001/ENGOT-ov43/GOG-3036) Read More
Phase: III
PANOVA-3: 1L Gemcit + nab-pac pancreatic
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read More
Phase: III
PANOVA-3: 1L Gemcit + nab-pac pancreatic
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read More
Phase: III
STAR Ph3 Nirap+Abirat+Pred mCRPC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001) Read More
Phase: III
STAR Ph3 Nirap+Abirat+Pred mCRPC
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001) Read More
Phase: III
STAR Abirat+pred +/- abemaciclib mCRPC
CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More
Phase: II
STAR Abirat+pred +/- abemaciclib mCRPC
CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More
Phase: II
STAR Rucaparib v PhysC mCRPC (TRITON3)
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More
Phase: III
STAR Rucaparib v PhysC mCRPC (TRITON3)
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More
Phase: III
STAR: PH2 Tuca+ Tras HER2+ CC
MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017) Read More
Phase: II
STAR: PH2 Tuca+ Tras HER2+ CC
MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017) Read More
Phase: II
STAR Ph1 CX-4945 Basal Cell Carcinoma
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07) Read More
Phase: I
STAR Ph1 CX-4945 Basal Cell Carcinoma
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07) Read More
Phase: I
STAR Ph2 Pemigatinib Solids FGFR
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More
Phase: II
STAR Ph2 Pemigatinib Solids FGFR
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More
Phase: II
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More
Phase: I/II
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More
Phase: I/II
STAR Ph2 Erdafitinib FGFR Solid Tumors
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) Read More
Phase: II
STAR Ph2 Erdafitinib FGFR Solid Tumors
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) Read More
Phase: II
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More
Phase: I/II
STAR Ph1/2 BLU667 thy, NSCLC, Sol tum
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More
Phase: I/II
STAR Ph3 FGFR erdafitinib urothelial
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More
Phase: III
STAR Ph3 FGFR erdafitinib urothelial
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More
Phase: III
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro
A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro
A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
STAR PH 2 ASG-22CE Urothelial Cancer
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More
Phase: I/II
STAR PH 2 ASG-22CE Urothelial Cancer
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More
Phase: I/II